164 related articles for article (PubMed ID: 28718401)
1. Targeting ATF5 in Cancer.
Angelastro JM
Trends Cancer; 2017 Jul; 3(7):471-474. PubMed ID: 28718401
[TBL] [Abstract][Full Text] [Related]
2. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
[TBL] [Abstract][Full Text] [Related]
3. Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.
Cates CC; Arias AD; Nakayama Wong LS; Lamé MW; Sidorov M; Cayanan G; Rowland DJ; Fung J; Karpel-Massler G; Siegelin MD; Greene LA; Angelastro JM
Oncotarget; 2016 Mar; 7(11):12718-30. PubMed ID: 26863637
[TBL] [Abstract][Full Text] [Related]
4. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis.
Hu M; Wang B; Qian D; Li L; Zhang L; Song X; Liu DX
Anticancer Res; 2012 Oct; 32(10):4385-94. PubMed ID: 23060563
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the human CHOP gene promoter by the stress response transcription factor ATF5 via the AARE1 site in human hepatoma HepG2 cells.
Yamazaki T; Ohmi A; Kurumaya H; Kato K; Abe T; Yamamoto H; Nakanishi N; Okuyama R; Umemura M; Kaise T; Watanabe R; Okawa Y; Takahashi S; Takahashi Y
Life Sci; 2010 Aug; 87(9-10):294-301. PubMed ID: 20654631
[TBL] [Abstract][Full Text] [Related]
6. Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD.
Sun X; Jefferson P; Zhou Q; Angelastro JM; Greene LA
Mol Cancer Res; 2020 Feb; 18(2):216-228. PubMed ID: 31676720
[TBL] [Abstract][Full Text] [Related]
7. ATF5 increases cisplatin-induced apoptosis through up-regulation of cyclin D3 transcription in HeLa cells.
Wei Y; Jiang J; Sun M; Chen X; Wang H; Gu J
Biochem Biophys Res Commun; 2006 Jan; 339(2):591-6. PubMed ID: 16300731
[TBL] [Abstract][Full Text] [Related]
8. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers.
Greene LA; Zhou Q; Siegelin MD; Angelastro JM
Cells; 2023 Feb; 12(4):. PubMed ID: 36831248
[TBL] [Abstract][Full Text] [Related]
9. Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas.
Arias A; Lamé MW; Santarelli L; Hen R; Greene LA; Angelastro JM
Oncogene; 2012 Feb; 31(6):739-51. PubMed ID: 21725368
[TBL] [Abstract][Full Text] [Related]
10. Activating transcription factor 5 enhances radioresistance and malignancy in cancer cells.
Ishihara S; Yasuda M; Ishizu A; Ishikawa M; Shirato H; Haga H
Oncotarget; 2015 Mar; 6(7):4602-14. PubMed ID: 25682872
[TBL] [Abstract][Full Text] [Related]
11. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy?
Sheng Z; Evans SK; Green MR
Oncotarget; 2010 Oct; 1(6):457-460. PubMed ID: 21311102
[TBL] [Abstract][Full Text] [Related]
12. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner.
Dluzen D; Li G; Tacelosky D; Moreau M; Liu DX
J Biol Chem; 2011 Mar; 286(9):7705-13. PubMed ID: 21212266
[TBL] [Abstract][Full Text] [Related]
13. Expression and targeting of transcription factor ATF5 in dog gliomas.
York D; Sproul CD; Chikere N; Dickinson PJ; Angelastro JM
Vet Comp Oncol; 2018 Mar; 16(1):102-107. PubMed ID: 28480569
[TBL] [Abstract][Full Text] [Related]
14. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines.
Monaco SE; Angelastro JM; Szabolcs M; Greene LA
Int J Cancer; 2007 May; 120(9):1883-90. PubMed ID: 17266024
[TBL] [Abstract][Full Text] [Related]
15. ATF5 promotes cell survival through transcriptional activation of Hsp27 in H9c2 cells.
Wang H; Lin G; Zhang Z
Cell Biol Int; 2007 Nov; 31(11):1309-15. PubMed ID: 17606386
[TBL] [Abstract][Full Text] [Related]
16. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest.
Gho JW; Ip WK; Chan KY; Law PT; Lai PB; Wong N
Cancer Res; 2008 Aug; 68(16):6743-51. PubMed ID: 18701499
[TBL] [Abstract][Full Text] [Related]
17. miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma.
Wang M; Hu M; Li Z; Qian D; Wang B; Liu DX
Biochem Biophys Res Commun; 2017 Sep; 490(4):1260-1267. PubMed ID: 28595907
[TBL] [Abstract][Full Text] [Related]
18. HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation.
Li G; Xu Y; Guan D; Liu Z; Liu DX
J Biol Chem; 2011 Jun; 286(23):20251-9. PubMed ID: 21521685
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells.
Li G; Li W; Angelastro JM; Greene LA; Liu DX
Mol Cancer Res; 2009 Jun; 7(6):933-43. PubMed ID: 19531563
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of the promoter of human ATF5 gene.
Wei Y; Ge Y; Zhou F; Chen H; Cui C; Liu D; Yang Z; Wu G; Gu J; Jiang J
J Biochem; 2010 Aug; 148(2):171-8. PubMed ID: 20423929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
